Advancing RNA Methylation for New Therapeutic Possibilities
We’re excited to share our latest profile article published in Nature Biopharma Dealmakers, highlighting our pioneering work with small-molecule activators (restoratives) of RNA methylation. This publication provides a compact overview of our developments in leveraging m6A restoration for treating neurodegenerative, neuropsychiatric, and metabolic disorders, including Parkinson’s disease, anxiety, and type 2 diabetes.
Our lead compound, CHMA1004, has shown promising preclinical results, demonstrating potential in improving behavior and promoting neuroprotection in animal models of neurodegeneration. Additionally, our ongoing research in metabolic diseases like diabetes shows exciting possibilities for future treatments.
It was a pleasure to collaborate with the Biopharma Dealmakers team – everything was very well organized, and we’re grateful that they reached out to us with this fantastic opportunity to share our work.
We invite you to read the full article to learn more about how our RNA methylation approach is driving new therapeutic avenues.
